This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the [18F]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of [18F]florbetaben uptake in the heart will be performed.

Start Date01 Apr 2025

Sponsor / Collaborator

Life Molecular Imaging Ltd.

[+1]

NCT06600880

/ Not yet recruitingPhase 1IIT

Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

Start Date01 Oct 2024

Sponsor / Collaborator

The Trustees of Columbia University in The City of New York

NCT05820191

/ Not yet recruitingPhase 2IIT

B-amyloid as a Marker for GBM Bioimaging

This project is aimed at improvement of glioblastoma (GBM) diagnostic strategies for discrimination of tumor progression and chemo- and radiotherapeutic treatment-related changes in brain tissue. The study will elucidate the diagnostic value of PET imaging with use of amyloid-β radioisotope tracer Amyvid (Florbetapir F18) for GBM. The results of the study will provide data for development of new approach for GBM diagnostics.

Start Date01 Jul 2024

Sponsor / Collaborator

Universidad Central del Caribe, Inc.

[+1]

100 Clinical Results associated with Florbetapir F-18

100 Translational Medicine associated with Florbetapir F-18

100 Patents (Medical) associated with Florbetapir F-18

454

Literatures (Medical) associated with Florbetapir F-18

01 Feb 2025·Journal of Nutrition Health & Aging

Impact of diabetes on the progression of Alzheimer’s disease via trajectories of amyloid–tau–neurodegeneration (ATN) biomarkers

Article

Author: Kim, Eosu ; Kim, Eun Woo ; Kim, Keun You

BACKGROUND:

Alzheimer's disease (AD) is characterized by the accumulation of abnormal proteins, such as β-amyloid and tau, in the brain, which precedes cognitive impairment. Although diabetes mellitus (DM) is a well-established risk factor for AD, few studies have investigated how the presence of DM affects the sequential pathogenesis of AD, specifically within the amyloid-tau-neurodegeneration (ATN) and cognition framework.

OBJECTIVES:

This study aims to investigate the trajectories of ATN biomarkers in relation to the presence of DM in the preclinical and prodromal stages of AD.

DESIGN:

Participants with normal cognition (CN) or mild cognitive impairment (MCI) at baseline were included. Subjects were followed for 12-192 months, with neuroimaging and cognitive assessments conducted at every 12 or 24 months.

SETTING:

This study utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.

PARTICIPANTS:

A total of 603 participants aged 55-90 years were included, comprising 284 CN (25 with DM, 259 without DM) and 319 MCI (39 with DM, 280 without DM) individuals.

MEASUREMENTS:

ATN biomarkers were identified using florbetapir positron emission tomography (PET), flortaucipir PET, and magnetic resonance imaging (MRI), respectively. Cognition was assessed using the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and Mini-Mental State Examination (MMSE). Moderation analysis was conducted to investigate the effect of DM on the association between ATN biomarkers of AD.

RESULTS:

Elevated amyloid standardized uptake value ratios (SUVRs) were associated with increased tau levels in the hippocampus, and this association was significantly enhanced by the presence of DM in MCI participants (p = 0.021). DM also strengthened the association between increased tau SUVR levels and neurodegeneration (indicated by decreased entorhinal cortical volumes; p = 0.005) in those with MCI. Furthermore, DM enhanced the association of decreased entorhinal (p = 0.012) and middle temporal cortex (p = 0.031) volumes with increased (worsened) CDR-SB scores in MCI participants. However, DM did not predict significant longitudinal changes in ATN pathology or cognitive decline in CN participants.

CONCLUSIONS:

Our study suggests that DM may increase the risk of AD by accelerating each step of the A-T-N cascade in the prodromal stage of AD, underscoring the importance of DM management in preventing the MCI conversion to AD.

01 Feb 2025·EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer’s disease

Article

Author: Laraib, Azka ; Feng, Yuxue ; Li, Qin ; Li, Xiaofeng ; Lin, Xiuqi ; Zhan, Jiehong

This study aimed to investigate the cross-sectional associations between regional Alzheimer's disease (AD) biomarkers, including tau, β-amyloid (Aβ), and brain volume, within the Papez circuit, and neuropsychological functioning across the preclinical and clinical spectrum of AD. We utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including 251 Aβ-positive participants. Participants were categorized into three groups based on the Clinical Dementia Rating (CDR): 73 individuals with preclinical AD (CDR = 0), 114 with prodromal AD (CDR = 0.5), and 64 with clinical AD dementia (CDR ≥ 1). Linear regression analyses, adjusted for age, gender, and education years, were employed to evaluate the associations between five regions of interest (the hippocampus, para-hippocampus, entorhinal cortex, posterior cingulate cortex, and thalamus) and five neuropsychological tests across the three imaging modalities. In the preclinical stage of AD, flortaucipir PET was associated with impaired global cognition and episodic memory (range standardized β = 0.255-0.498, p < 0.05 corrected for multiple comparisons), while florbetapir PET and brain volume were marginally related to global cognition (range standardized β = 0.221-0.231, p < 0.05). In the clinical stages of AD (prodromal and dementia), both increased flortaucipir uptake and decreased brain volume were significantly associated with poorer global neuropsychological and episodic memory performance (range standardized β = 0.222-0.621, p < 0.05, most regions of interest survived correction for multiple comparisions). However, a slight relationship was observed between florbetapir uptake and poorer global cognitive function. The regions most affected by flortaucipir PET were the hippocampus, para-hippocampus, and posterior cingulate cortex. During the clinical stages, the hippocampus and entorhinal cortex exhibited the most significant volumetric changes. Tau PET and brain volume measurements within the Papez circuit are more sensitive indicators of early cognitive deficits in AD than Aβ PET. Furthermore, during the clinical stages of AD, both flortaucipir PET and brain volume of the Papez circuit are closely correlated with cognitive decline. These findings underscore the importance of integrating multiple biomarkers for the comprehensive evaluation of AD pathology and its impact on cognition.

01 Jan 2025·STROKE

Do Amyloid Cerebral Deposits Influence the Long-Term Poststroke Cognitive Outcome?: The IDEA3 Study

Article

Author: Wollenweber, Frank A. ; Deramond, Hervé ; Marchal, Etienne ; Shields, Trevor ; Loas, Gwénolé ; Diouf, Momar ; Courselle-Arnoux, Audrey ; Picard, Carl ; Berrissoul, Hassan ; Despretz-Wannepain, Sandrine ; Barbay, M. ; Meyer, Marc-Etienne ; Trinchard, Niels ; Leclercq, Claire ; Constans, Jean-Marc ; Lamy, Chantal ; Canaple, Sandrine ; Roussel, Martine ; Godefroy, Olivier

BACKGROUND::

Although the presence of amyloid deposits is associated with a more severe cognitive status in patients with stroke at baseline, its influence on the subsequent cognitive outcome has not been extensively assessed. The primary objective of the present study of the IDEA3 (Imagerie des dépôts amyloïdes cérébraux par florbetapir AV-45 et diagnostic des déficits cognitifs et démence post Accident Vasculaire Cérébral) cohort was to determine the influence of amyloid positron emission tomography (PET) status on the 5-year cognitive outcome.

METHODS::

This longitudinal study performed in Amiens University Hospital (inclusions: October 2014 to October 2019; last visits: October 2018 to February 2023) has included 91 patients with stroke (ischemic stroke, 89%; hemorrhagic stroke, 11%) with florbetapir PET data at baseline (positive, n=14). Patients underwent annually comprehensive clinical and cognitive assessments for 5 years after the PET scan. The primary outcome was incident dementia; secondary outcomes were incident cognitive impairment, total prevalence of cognitive impairment, and modified Rankin Scale score.

RESULTS::

A survival analysis (mean poststroke follow-up, 80.4±27 months) showed that the incidence of incident dementia was higher in the PET-positive patients (odds ratio, 9.6 [95% CI, 2.5–36.9]; P =0.001), as was the incidence of incident cognitive impairment (odds ratio, 10 [95% CI, 1.9–52.3]; P =0.003). A Cox regression analysis showed that the association between amyloid status and the incidences of dementia ( P =0.001) and cognitive impairment ( P =0.007) was still significant after adjustment for age, education, prestroke modified Rankin Scale score and cognitive impairment, stroke type, and the PET status×stroke type interaction. Considering the overall prevalence at the last follow-up in the whole study population (n=91 patients), PET positivity was associated with an elevated risk of dementia (odds ratio, 6 [95% CI, 1.76–20.5]; P =0.002) and poststroke cognitive impairment (odds ratio, 6.25 [95% CI, 1.77–22]; P =0.002). The final modified Rankin Scale score did not differ ( P =0.3) according to PET status.

CONCLUSIONS::

Our results demonstrate the major impact of amyloid deposition on the stroke outcome and emphasized the need for comprehensive etiologic workup in patients with poststroke cognitive impairment.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02813434.

News (Medical) associated with Florbetapir F-18

08 Jan 2025

·www.prnewswire.com

Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer's Disease

Largest DxA investment to date supports development of Alamar's ARGO™ DX System and future in vitro diagnostic tests NEW YORK and FREMONT, Calif., Jan. 8, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF)'s Diagnostics Accelerator (DxA) today announced a $10M investment in Alamar Biosciences, Inc. This landmark investment, the largest in DxA history, will expedite the translation of the ARGO-HT research platform into an FDA-cleared system to support the development of in vitro diagnostic (IVD) tests – the gold standard of diagnostics. Alamar's ARGO HT System automates high-throughput NULISA™ assays, offering ultrasensitive protein detection and multiplexing for analyzing blood-based biomarkers related to Alzheimer's and other dementias. Continue Reading Alamar Biosciences logo "In cancer and other diseases of aging, we have biomarker panels that allow clinicians to better differentiate from many underlying causes of the disease and more importantly, how to tailor treatments based on each patient's individual biomarker profile," said Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF. "There is a pressing need to have biomarker panels for Alzheimer's patients so we can better diagnose and develop new treatments. Alamar's innovative platform provides the opportunity for a first of its kind blood panel in Alzheimer's, which will be an important step as we move forward to delivering a more personalized approach for patients." "The powerful combination of ultra-high sensitivity and multiplexing unlocks the potential to measure novel biomarker signatures, enabling differential diagnosis in neurodegeneration," said Niranjan Bose, Managing Director, Health and Life Sciences at Gates Ventures. "The investment in the development of ARGO DX focuses on translating this capability onto a scalable platform for widespread clinical use. We are excited to partner with the Alamar team to bring this vision to reality and advance the molecular diagnostics landscape in Alzheimer's disease." The holy grail for Alzheimer's diagnostics is to develop an accessible and scalable blood panel that can detect multiple biomarkers, providing clinicians with a better understanding of each patient's individual disease biology. Alamar's NULISA™ technology is unique in that it enables ultra-high sensitivity with the ability to test for multiple targets at once. "Experts in the field have showcased the performance of the NULISA technology in detecting essentially all the important biomarkers in blood for Alzheimer's and related dementias," said Yuling Luo, Ph.D., Founder, Chairman, and CEO of Alamar Biosciences, Inc. "The ARGO DX platform can potentially revolutionize the biomarker space by allowing researchers to go from discovery to detection of biomarker panels that stratify patient subsets and disease factors that would otherwise have gone unnoticed." "A diagnostic platform such as Alamar's, that can detect and measure multiple disease pathways, will be instrumental in paving the way for early detection, biology of aging-based differential diagnosis, allowing for a precision medicine approach in Alzheimer's," commented Dr. Fillit. This recent investment in Alamar reflects the DxA's larger vision to accelerate the development of new biomarkers and diagnostic tools to enable early detection and diagnosis of Alzheimer's. To date, the DxA has invested more than $80 million in nearly 70 projects, underscoring its commitment to bringing accessible, affordable, and scalable diagnostics to patients struggling with Alzheimer's disease. Along with blood tests, the DxA's diverse portfolio includes retinal scans and digital tools that will not only provide patients with early and accurate diagnoses but also work in tandem and have the potential to be used for screening, prognostic, and prevention efforts. About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $360 million to fund over 760 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: . ABOUT THE DIAGNOSTICS ACCELERATOR (DxA) The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers. About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com. SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

14 Nov 2024

·www.prnewswire.com

New Investment from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker

The DxA partners with Dr's Henrik Zetterberg and Nicholas Ashton to create critical standardized reference materials for leading Alzheimer's blood biomarker, p-Tau217, to ensure consistency across global research and clinical settings NEW YORK, Nov. 14, 2024 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF)'s Diagnostics Accelerator today announced a $1.18M investment in the University of Gothenburg (Sweden) to develop standardization reference materials for phosphorylated tau 217 (p-tau217) blood tests, the leading diagnostic blood biomarker for Alzheimer's disease. The project will be led by Henrik Zetterberg, MD, PhD and Nicholas Ashton, PhD, from the University of Gothenburg and Banner Health, who are both internationally recognized for their leadership and advancement of fluid biomarkers for central nervous system diseases such as Alzheimer's. The primary objective of the project is to create a certified reference material that assay developers can use as a baseline to test against when developing a p-tau217 blood test. Continue Reading Diagnostics Accelerator "Blood tests are emerging as one of the most transformative developments in Alzheimer's diagnosis and treatment," said Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF. "With science accelerating at an unprecedented pace, it is critical that we develop tools that provide a consistent benchmark across all clinical settings. This investment will enhance the accuracy and comparability of test results so patients across the globe have access to reliable diagnostics so they can get the right treatment options for this debilitating disease." Similar efforts to standardize amyloid beta 1-42 (Aβ42) and total tau (t-tau) in cerebrospinal fluid (CSF), along with advances in imaging and amyloid testing, have significantly advanced Alzheimer's research and diagnosis. These biomarkers are crucial for understanding the disease's underlying biology as well as treating the disease. Applying these insights to standardizing p-tau in blood has the potential to become essential to diagnosing Alzheimer's, offering a unique opportunity to move the process forward for more patients. "Providing researchers with evidence-based certified guidelines will help companies calibrate more uniform assays," said Henrik Zetterberg, MD, PhD, Chief Physician and Professor at Institute of Neuroscience and Physiology at University of Gothenburg in Sweden as well as the 2024 Goodes Prize winner. "There is an urgent need to standardize p-tau217 for global clinical implementation. Support from the DxA is critical to project success and is indicative of its leadership in the biomarker diagnostics field." The DxA has invested more than $70 million in nearly 70 projects, underscoring its commitment to bringing accessible, affordable, and scalable diagnostics to patients struggling with Alzheimer's disease. Along with blood tests, the DxA's diverse portfolio includes retinal scans and digital tools that will not only provide patients with early and accurate diagnoses, but also have the potential to be used for screening, prognostic, and prevention efforts. As the Alzheimer's field continues to evolve rapidly, the way the disease is perceived, diagnosed, and treated will also mature. Adding the parameters built into standardized guidelines will ensure that meaningful momentum continues in the pursuit of accurate, accessible, and effective diagnostics. "Blood-based biomarkers like p-tau217 will be one of the many novel biomarkers that will be essential to laying the foundation for combination therapies and a precision medicine approach, representing the future of Alzheimer's treatment. These new tools will move Alzheimer's diagnostics closer to those of other diseases of aging, such as cancer, where personalized treatments are used based on each patient's unique biomarker profile," said Dr. Fillit. About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: . About The Diagnostics Accelerator (DxA) The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers. SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Diagnostic Reagents

07 Oct 2024

·www.prnewswire.com

New Considerations for Accelerating Combination Therapy Trials to be Showcased at 2024 Clinical Trials on Alzheimer's Disease Conference

Combination Therapy Approach Stemming from ADDF Advisory Board Expected to Shape the Next Generation of Alzheimer's Treatments Novel Therapies Guided by the Biology of Aging Take Center Stage at CTAD, Reflecting the Evolution of the Drug Pipeline NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will be leading a roundtable, "Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments," at the 2024 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 29th through November 1st in Madrid, Spain. Moderated by Jeffrey Cummings, MD, ScD, Joy Chambers-Grundy Professor of Brain Science at the School of Integrated Health Sciences at University of Nevada, Las Vegas (UNLV), the panel will feature Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF alongside leading experts from industry, academia, and clinical research. The panel takes place on Wednesday, October 30th at 1:45pm CET and will expand upon the recommendations of an expert advisory board—convened by the ADDF at the beginning of the year—that recently provided key considerations on how best to approach and accelerate combination therapy trials for Alzheimer's. "Decades of research has brought us to a pivotal point in the field where the learnings and advances we've gained can now be applied to a robust and diverse pipeline, create a promising path forward for combination therapy trials. These more complex trials—that will look to combine anti-amyloids with novel therapies—are critical to developing the next generation of treatments that will enable precision medicine approach," notes Dr. Fillit. "The patients and families living with this debilitating disease cannot afford for us to take our foot off the gas, we must maintain the momentum toward developing a much-needed personalized and multi-pronged solution." Dr. Fillit will also chair a session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," on Thursday, October 31st at 11:25am CET. This session will highlight several promising therapeutic programs exploring the underlying aging pathologies contributing to the onset of Alzheimer's, which are indicative of the larger drug pipeline where nearly 75% of Alzheimer's drugs in clinical trials are exploring novel targets beyond amyloid and tau. CTAD will feature several key sessions from ADDF-funded investigators, whose work in drug development and biomarkers is shaping and leading the field towards the holy grail of Alzheimer's treatments—combination therapy and precision medicine, similar to cancer care. Dr. Fillit will participate in several sessions around timely developments: Roundtable: "Forging the Path Forward: Capitalizing on Recent Alzheimer's Momentum through Strategic Investments in Novel Therapeutics" on Wednesday, October 30th at 1:45pm CET Moderator: Jeffrey Cummings, MD, ScD (UNLV) Panelists: Howard Fillit, MD (ADDF), Michael Gold, MD (Compass Pathways), Suzanne Hendrix, PhD (Pentara), Mark Mintun, MD, (Eli Lilly), and Jin Zhou, PhD (Eisai) Session: "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease" on Thursday, October 31st at 11:25 am CET Chair: Howard Fillit, MD Additional sessions from ADDF-funded investigators include: Oral Communication: "Results from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer's Disease" with Cognition Therapeutics on Tuesday, October 29th at 5:55pm CET Late Breaker: "Safety and Preliminary Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer's Disease – Interim Data from a Phase 1/2, Open-Label, 52-Week, Multicenter Study" with Lexeo on Wednesday, October 30th at 10:50am CET Late Breaker: "Plasma p-tau217 and related CSF proteomic markers of pathological progression are slowed by p75NTR modulation: A Phase 2a trial of LM11A31 in Alzheimer's disease" with PharmatophiX on Thursday, October 31st at 8:30am CET To view the full program for the 2024 CTAD conference, visit the conference webpage. About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

100 Deals associated with Florbetapir F-18

External Link

KEGG	Wiki	ATC	Drug Bank
D09617	Florbetapir F-18	V09AX05	DB09149

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	EU	Eli Lilly Nederland BV	14 Jan 2013
Alzheimer Disease	IS	Eli Lilly Nederland BV	14 Jan 2013
Alzheimer Disease	LI	Eli Lilly Nederland BV	14 Jan 2013
Alzheimer Disease	NO	Eli Lilly Nederland BV	14 Jan 2013
Contrast agents	US	Avid Radiopharmaceuticals, Inc.	06 Apr 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dementia due to Alzheimer's disease (disorder)	Phase 3	CN	JYAMS PET Research & Development Ltd.	20 Oct 2022
Cognitive Dysfunction	Phase 3	US	Avid Radiopharmaceuticals, Inc.	01 Jul 2011
Mild cognitive disorder	Phase 3	-	Avid Radiopharmaceuticals, Inc.	01 Feb 2011
Chronic Traumatic Encephalopathy	Phase 2	US	Avid Radiopharmaceuticals, Inc.	01 Jun 2014
Lewy Body Disease	Phase 2	US	Avid Radiopharmaceuticals, Inc.	01 Mar 2010
Striatonigral Degeneration	Phase 2	US	Avid Radiopharmaceuticals, Inc.	01 Mar 2010
Frontotemporal Dementia	Phase 2	GB	Avid Radiopharmaceuticals, Inc.	01 Sep 2009
Parkinson Disease	Phase 2	US	Avid Radiopharmaceuticals, Inc.	01 Jan 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2024	Not Applicable	-	-	Active tACS	zogvizoiou(sytltxbwco) = tbmtkjulah voeggwkzbn (cwosolkbtq )	-	09 Jun 2024
SNMMI2024	Not Applicable	-	-	Sham tACS	zogvizoiou(sytltxbwco) = zfuqrmlerj voeggwkzbn (cwosolkbtq )	-	09 Jun 2024
SNMMI2022	Not Applicable	-	-	Random Forest	wkipuxtktw(xkuoedrhxm) = extmzquxii opgetgiybu (ylxkymkldz ) View more	-	08 Aug 2022
SNMMI2022	Not Applicable	-	-	Random Forest (K-Means Clustering)	wkipuxtktw(xkuoedrhxm) = jdfefkxlcj opgetgiybu (ylxkymkldz ) View more	-	08 Aug 2022
NCT01683825 (CTgov)	Phase 4	Senile cardiac amyloidosis	23	F-18 florbetapir PET	ifhyuidlwq(oudotvhxsz) = wjxfjmxhjq dcummxvvcd (bdexkgwuzx, yuldokkqqc - awbqnzdkiw) View more	-	13 Apr 2022
NCT01767493 (CTgov)	Phase 4	Multiple Sclerosis, Relapsing-Remitting	19	[18F]Florbetapir PET imaging	evkvvgdpqa(soltskvalg) = tzxnzkkqvb wivpapapxa (tkcoxywzhf, dxalcswczv - rwkwxaozai) View more	-	27 Aug 2021
AAIC2018	Not Applicable	Alzheimer Disease amyloid beta (Aβ)	-	[18F]FLORBETAPIR (AD patients)	eyfqokyiqa(fsqasbzocw) = icfbpcvqhj mercytsaru (kqmarefkyj )	-	01 Jul 2018
AAIC2018	Not Applicable	Alzheimer Disease amyloid beta (Aβ)	-	[18F]FLORBETAPIR (Controls)	eyfqokyiqa(fsqasbzocw) = hecnlxnydv mercytsaru (kqmarefkyj )	-	01 Jul 2018
NCT01518374 (CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	1,768	Florbetapir F 18	crnnjdcapr(idtyvancsp) = tvktbvdaxm idbontpmnx (ewmucyilce, wgortcwvjq - rufwmxqmvu) View more	-	14 Jun 2018
SNMMI2016	Not Applicable	Alzheimer Disease	-	Amyloid PET Tracer (AD Patients)	rfzpvwgriv(xsjuxdsimd) = Receiver Operating Characteristics (ROC) showed the Area-under-the-ROC-Curve of 0.90±0.018 using 3D-SSP-PCLD and 0.91±0.018 3D-SSP-SUVR, indicating a nearly identical discriminatory power for normal controls vs AD patients kjwtrlpyli (vvrrpxnohy ) View more	-	24 May 2016
ISC2016	Not Applicable	Cerebral Amyloid Angiopathy	-	Florbetapir (CAA patients)	ruldyckjwc(yuqqqngzrv) = wysupmphmp zbsieshlcr (eewgovrtum )	-	01 Feb 2016
ISC2016	Not Applicable	Cerebral Amyloid Angiopathy	-	Florbetapir (HTN-ICH patients)	ruldyckjwc(yuqqqngzrv) = bqvvckmmey zbsieshlcr (eewgovrtum )	-	01 Feb 2016
CTAD2015	Not Applicable	-	-	Genentech Tau Probe 1 ([18F]GTP1)	egfqyopuog(xmzvncdfos) = kiinkzfecs gcapmnzuut (yvlrnwtgmp, 4.3)	-	04 Nov 2015
NCT02051790 (CTgov)	Phase 4	Alzheimer Disease	241	florbetapir F 18	tvqdxszwwa(dfaxrjefza) = wehzkrkjpx lcqoyhsqbf (uzdbkfhgta, qdsarzdizd - msvfqmttym) View more	-	28 Sep 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis